Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Tarsus Pharmaceuticals, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 205
- +13 vs. Q1 2025
- Shares held
- 46.1M
- +2.20M (+5.0%) vs. Q1 2025
- Total value
- $1.87B
- −$388.3M (−17.2%) vs. Q1 2025
- New holders
- 43
- 89 more added
- Sold out
- 30
- 49 more reduced
3 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $2.98B |
| Q1 2026 | 253 | $3.17B |
| Q4 2025 | 246 | $3.61B |
| Q3 2025 | 220 | $2.67B |
| Q2 2025 | 205 | $1.87B |
| Q1 2025 | 195 | $2.26B |
| Q4 2024 | 195 | $2.23B |
| Q3 2024 | 162 | $1.43B |
| Q2 2024 | 148 | $1.09B |
| Q1 2024 | 157 | $1.43B |
| Q4 2023 | 116 | $652.0M |
| Q3 2023 | 105 | $529.4M |
| Q2 2023 | 92 | $387.3M |
| Q1 2023 | 74 | $252.1M |
| Q4 2022 | 69 | $301.0M |
| Q3 2022 | 75 | $350.8M |
| Q2 2022 | 73 | $291.7M |
| Q1 2022 | 51 | $222.2M |
| Q4 2021 | 43 | $294.2M |
| Q3 2021 | 44 | $277.4M |
| Q2 2021 | 44 | $378.5M |
| Q1 2021 | 41 | $410.4M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Tarsus Pharmaceuticals, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 2,454,797 | $99.4M | 5.03% | 00.0% | Unchanged |
| Jennison Associates LLC | 2,467,998 | $100.0M | 0.06% | −24,642−1.0% | Reduced |
| Paradigm Biocapital Advisors LP | 2,976,099 | $120.6M | 5.15% | +365,902+14.0% | Added |
| RTW Investments, LP | 3,111,680 | $126.1M | 1.80% | −204,352−6.2% | Reduced |
| BlackRock, Inc. | 3,792,185 | $153.6M | 0.00% | +638,457+20.2% | Added |
| Cutter Capital Management, LP | 0 | $0 | 0.00% | −205,000−100.0% | Sold out |
| Atika Capital Management LLC | 0 | $0 | 0.00% | −144,400−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −81,331−100.0% | Sold out |
| Castleark Management LLC | 0 | $0 | 0.00% | −74,920−100.0% | Sold out |
| Essex Investment Management Co LLC | 0 | $0 | 0.00% | −54,447−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −52,413−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −28,173−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −18,236−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −16,388−100.0% | Sold out |
| Numerai GP LLC | 0 | $0 | 0.00% | −14,459−100.0% | Sold out |
| Allostery Investments LP | 0 | $0 | 0.00% | −13,600−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −11,416−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,456−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −9,802−100.0% | Sold out |
| OmniStar Financial Group, Inc. | 0 | $0 | 0.00% | −8,367−100.0% | Sold out |
| CIBC World Markets Corp | 0 | $0 | 0.00% | −8,260−100.0% | Sold out |
| Springhill Fund Asset Management (HK) Co Ltd | 0 | $0 | 0.00% | −7,076−100.0% | Sold out |
| Thoroughbred Financial Services, LLC | 0 | $0 | 0.00% | −5,510−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −5,284−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −5,214−100.0% | Sold out |
| Sandia Investment Management LP | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −4,400−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −4,100−100.0% | Sold out |
| BI Asset Management Fondsmaeglerselskab A/S | 0 | $0 | 0.00% | −579−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −89−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Grant/GrossMendelsohn, LLC | – | – | – | – | Not filed |
| Callan Capital, LLC | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |